TW509687B - Novel piperazine derivatives having combined 5HT1A, 5HT1B and 5HT1D recept or antagonist activity and their use for the treatment and prophylaxis of various CNS disorders - Google Patents

Novel piperazine derivatives having combined 5HT1A, 5HT1B and 5HT1D recept or antagonist activity and their use for the treatment and prophylaxis of various CNS disorders Download PDF

Info

Publication number
TW509687B
TW509687B TW087105843A TW87105843A TW509687B TW 509687 B TW509687 B TW 509687B TW 087105843 A TW087105843 A TW 087105843A TW 87105843 A TW87105843 A TW 87105843A TW 509687 B TW509687 B TW 509687B
Authority
TW
Taiwan
Prior art keywords
indole
dihydro
small
methyl
phenylaminocarbonyl
Prior art date
Application number
TW087105843A
Other languages
English (en)
Chinese (zh)
Inventor
Laramie Mary Gaster
Harshad Kantilal Rami
Paul Adrian Wyman
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9707829.9A external-priority patent/GB9707829D0/en
Priority claimed from GBGB9801882.3A external-priority patent/GB9801882D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of TW509687B publication Critical patent/TW509687B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
TW087105843A 1997-04-18 1998-04-17 Novel piperazine derivatives having combined 5HT1A, 5HT1B and 5HT1D recept or antagonist activity and their use for the treatment and prophylaxis of various CNS disorders TW509687B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9707829.9A GB9707829D0 (en) 1997-04-18 1997-04-18 Novel compounds
GBGB9801882.3A GB9801882D0 (en) 1998-01-29 1998-01-29 Novel compounds

Publications (1)

Publication Number Publication Date
TW509687B true TW509687B (en) 2002-11-11

Family

ID=26311401

Family Applications (1)

Application Number Title Priority Date Filing Date
TW087105843A TW509687B (en) 1997-04-18 1998-04-17 Novel piperazine derivatives having combined 5HT1A, 5HT1B and 5HT1D recept or antagonist activity and their use for the treatment and prophylaxis of various CNS disorders

Country Status (17)

Country Link
EP (1) EP0975593A1 (fr)
JP (1) JP2001524116A (fr)
KR (1) KR20010006487A (fr)
CN (1) CN1260781A (fr)
AR (1) AR013076A1 (fr)
AU (1) AU732863B2 (fr)
BR (1) BR9809092A (fr)
CA (1) CA2288662A1 (fr)
CO (1) CO4950608A1 (fr)
HU (1) HUP0001123A3 (fr)
IL (1) IL132409A0 (fr)
NO (1) NO995065L (fr)
NZ (1) NZ500252A (fr)
PL (1) PL336317A1 (fr)
TR (1) TR199902590T2 (fr)
TW (1) TW509687B (fr)
WO (1) WO1998050358A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725931D0 (en) * 1997-12-05 1998-02-04 Smithkline Beecham Plc Novel compounds
EP1101759A4 (fr) 1998-07-31 2001-12-12 Nippon Soda Co Composes phenylazole, procede de production desdits composes et medicaments pour le traitement de l'hyperlipidemie
GB9827882D0 (en) * 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
CA2378047A1 (fr) * 1999-07-15 2001-01-25 Methvin Isaac Composes heterocycliques destines au traitement de la migraine
HUP0202787A3 (en) 1999-09-25 2003-12-29 Smithkline Beecham Plc Piperazine derivatives as 5-ht1b antagonists, process for their preparation and pharmaceutical compositions containing them
WO2001032626A1 (fr) * 1999-11-05 2001-05-10 Smithkline Beecham P.L.C. Derives d'isoquinoline et de quinazoline dotes d'une activite combinee de recepteur 5ht1a, 5ht1b et 5ht1d
GB9926303D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
DE10051981A1 (de) 2000-10-20 2002-05-02 Bayer Ag Substituierte Phenyluracile
GB0106419D0 (en) 2001-03-15 2001-05-02 Smithkline Beecham Plc Novel compounds
GB0106586D0 (en) * 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
KR100600240B1 (ko) * 2001-06-07 2006-07-13 에프. 호프만-라 로슈 아게 5-ｈｔ6 수용체 친화도를 갖는 신규한 인돌 유도체
EP2033953A1 (fr) 2002-02-15 2009-03-11 Glaxo Group Limited Modulateurs des récepteurs vanilloides
ATE316523T1 (de) 2002-05-13 2006-02-15 Hoffmann La Roche Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
AU2004299201B2 (en) 2003-12-09 2009-12-03 F. Hoffmann-La Roche Ag Benzoxazine derivatives and uses thereof
CN101896461A (zh) * 2007-12-13 2010-11-24 安姆根有限公司 γ分泌酶调节剂
CA2794153C (fr) 2010-03-25 2018-01-02 Glaxosmithkline Llc Derives d'indoline substitue comme inhibiteurs de perk
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN102924330A (zh) * 2012-09-03 2013-02-13 华东理工大学 一种规模化制备5-氨基-1-萘腈的方法
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN103467374A (zh) * 2013-08-30 2013-12-25 江苏弘和药物研发有限公司 一种8-溴-4-羧基喹啉的合成方法
CN109336883B (zh) 2013-12-20 2022-06-14 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
CN115197099A (zh) * 2022-05-30 2022-10-18 安徽昊帆生物有限公司 N-Boc-1，4-苯二胺的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119920D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
EP0533268B1 (fr) * 1991-09-18 2001-08-16 Glaxo Group Limited Dérivés de benzanilide comme 5-HT1D antagonistes
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
EP0712397B1 (fr) * 1993-08-06 1999-04-21 Smithkline Beecham Plc Derives amides employes comme antagonistes du recepteur 5ht1d
JPH09504004A (ja) * 1993-08-20 1997-04-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ｄレセプター拮抗薬用アミドおよび尿素誘導体
WO1995006637A1 (fr) * 1993-09-03 1995-03-09 Smithkline Beecham Plc Nouveaux derives d'indole et d'indoline en tant qu'antagonistes du recepteur de 5ht1d

Also Published As

Publication number Publication date
AU732863B2 (en) 2001-05-03
BR9809092A (pt) 2002-01-22
AU7431098A (en) 1998-11-27
PL336317A1 (en) 2000-06-19
AR013076A1 (es) 2000-12-13
HUP0001123A3 (en) 2002-04-29
JP2001524116A (ja) 2001-11-27
HUP0001123A2 (hu) 2001-04-28
CO4950608A1 (es) 2000-09-01
CA2288662A1 (fr) 1998-11-12
TR199902590T2 (xx) 2000-06-21
WO1998050358A1 (fr) 1998-11-12
NZ500252A (en) 2001-07-27
NO995065D0 (no) 1999-10-15
NO995065L (no) 1999-10-15
CN1260781A (zh) 2000-07-19
KR20010006487A (ko) 2001-01-26
EP0975593A1 (fr) 2000-02-02
IL132409A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
TW509687B (en) Novel piperazine derivatives having combined 5HT1A, 5HT1B and 5HT1D recept or antagonist activity and their use for the treatment and prophylaxis of various CNS disorders
JP6528957B2 (ja) Ｔｒｋ阻害化合物
JP6689805B2 (ja) カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
JP5977779B2 (ja) ２−（２，４，５−置換−アニリノ）ピリミジン化合物
JP4183193B2 (ja) 含窒素芳香環誘導体
KR101477553B1 (ko) 이소인돌론 화합물 및 대사성 글루타메이트 수용체증강제로서 이들의 용도
AU2013339167B2 (en) Novel amine derivative or salt thereof
AU2016262572B2 (en) EBNA1 inhibitors and methods using same
TW200829591A (en) Organic compounds
TW200813022A (en) Organic compounds
TW200540169A (en) Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
TW200403223A (en) Novel compounds
WO2001087834A1 (fr) Antagoniste de l'hormone de concentration de la melanine
CA2877474A1 (fr) Composes et ses utilisations therapeutiques
CA2045359C (fr) 1-indolyalkyl-4-(alkoxypyrimidinyl)piperazines
TW200900068A (en) Novel N,N'-2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as IKK inhibitors
TW200804338A (en) New compounds
TW200944520A (en) Spiro compounds as NPY Y5 receptor antagonists
EA019723B1 (ru) ИНГИБИТОРЫ cMET
TW201136918A (en) Novel substituted triazole derivatives as gamma secretase modulators
TW201204361A (en) Nitrogen-containing heterocyclic compound having kynurenine production inhibitory activity
TWI583687B (zh) ２－氧雜－５－氮雜雙環［２．２．１］庚－３－基衍生物
CZ20021038A3 (cs) Piperazinové deriváty jako antagonisté 5-HT1B
EP2888248B1 (fr) 4-pyridones substituées et leur utilisation comme inhibiteurs de l'activité de l'élastase neutrophile
TW200815397A (en) Substituted pyridyl amide compounds as modulators of the histamine H3 receptor